Driven by an 89% year-on-year jump in Q3 net profit to RMB2.46bn, a 21% rise in revenue to RMB8.95bn, innovative drugs reaching nearly 65% of revenue and recognition of out-licensing income, Hengrui Pharma H-shares opened higher and extended gains in the Hong Kong morning session, last at HK$49.04 at 09:31 BJ, up 9.66% from the previous close of HK$44.72, with an intraday range of HK$45.98-49.20 and turnover of about HK$21.8m. The opening print was HK$46.00, and the session high of HK$49.20 marked a 10.02% advance from the previous close. The stock now sits above its MA20 of HK$47.95 and MA60 of HK$48.80, yet remains down 33.82% year-to-date, 39.68% below its 52-week high of HK$81.30 and 13.99% above its 52-week low of HK$43.02; market capitalisation is HK$324.8bn, with PE at 31.39x and PB at 4.17x. Though JPMorgan reduced its long position in the H-shares, the price is still nearly 40% below the 52-week high.